Long-term Nexviazyme Therapy Improves Lung Function, Mobility in LOPD

Long-term treatment with Nexviazyme (avalglucosidase alfa) safely and effectively improves lung function and walking ability in children and adults with late-onset Pompe disease (LOPD), according to nearly two years of data from the Phase 3 COMET trial. These findings, along with positive long-term results from the Phase 2…

Avalglucosidase Alfa, Next-Generation ERT, Under Review in Europe

The European Medicines Agency agreed to begin reviewing Sanofi Genzyme’s application requesting the approval of avalglucosidase alfa, its investigational enzyme replacement therapy (ERT) for people with Pompe disease. According to a press release, a regulatory decision is expected in the second half of 2021, and if…

Sanofi’s Next-generation ERT Halts Progression of Pompe Disease in Patients, Interim Trial Data Show

Sanofi Genzyme’s next-generation enzyme replacement therapy (ERT), avalglucosidase alfa, safely halts disease progression in people with Pompe disease, according to interim data from two Phase 2 clinical trials. The trial’s results were the focus of oral and poster presentations at the 16th Annual WORLDSymposium, held…